Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Viatris in Egypt, a part of global healthcare company Viatris, announced the launch of Norvasc Val, a combination therapy for ...

Shares of medication company Viatris (NASDAQ:VTRS) fell 3.8% in the afternoon session after its experimental therapy for ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Viatris has aggressively deleveraged, now poised for growth with a robust pipeline. See why a Strong Buy rating is justified ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Indiana Attorney General Todd Rokita has secured $720 million in settlements with eight drug makers that manufacture opioid ...

Indiana Attorney General Todd Rokita announced the state’s 11th opioid settlement as Indiana’s Attorney General, securing ...

Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess ...